Find Taurolidine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 19388-87-5, Taurolidin, Taurolin, Cyclo-taurolidine, (cyclo)-taurolidine, 4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide
Molecular Formula
C7H16N4O4S2
Molecular Weight
284.4  g/mol
InChI Key
AJKIRUJIDFJUKJ-UHFFFAOYSA-N
FDA UNII
8OBZ1M4V3V

Taurolidine
Taurolidine is a synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.
1 2D Structure

Taurolidine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide
2.1.2 InChI
InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2
2.1.3 InChI Key
AJKIRUJIDFJUKJ-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CS(=O)(=O)NCN1CN2CCS(=O)(=O)NC2
2.2 Other Identifiers
2.2.1 UNII
8OBZ1M4V3V
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4,4'-methylenebis-(tetrahydro-1,2,4-thiadiazine- 1,1-dioxide)

2. Bis(1,1-dioxo-perhydro-1,2,4-thiadiazinyl-4)methane

3. Bis- (1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)methane

4. Tauroflex

5. Taurolin

6. Tauroline

2.3.2 Depositor-Supplied Synonyms

1. 19388-87-5

2. Taurolidin

3. Taurolin

4. Cyclo-taurolidine

5. (cyclo)-taurolidine

6. 4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide

7. 8obz1m4v3v

8. 4,4'-methylenebis(1,2,4-thiadiazinane 1,1-dioxide)

9. Tauroline

10. 4,4'-methylenebis(tetrahydro-1,2,4-thiadiazine 1,1-dioxide)

11. Taurolidine (inn)

12. W-3100m

13. Taurolidine [inn]

14. Taurolidina

15. Taurolidinum

16. Taurolidinum [inn-latin]

17. Taurolidina [inn-spanish]

18. Taurolidine [inn:ban]

19. Einecs 243-016-5

20. Unii-8obz1m4v3v

21. Taurolidine [mi]

22. Taurolidine [mart.]

23. Schembl65313

24. Taurolidine [who-dd]

25. Chembl2105420

26. Dtxsid00173001

27. Chebi:135173

28. Amy28822

29. S4885

30. Taurolidine, >97% (nmr), Powder

31. Zinc19322537

32. Taurolock Component Taurolidine

33. 2h-1,2,4-thiadiazine, 4,4'-methylenebis[tetrahydro-, 1,1,1',1'-tetraoxide

34. Akos015896472

35. Ac-1423

36. Ccg-267310

37. Cs-w012238

38. Db12473

39. Hy-w011522

40. Ls-13376

41. Ft-0617113

42. T3980

43. D07146

44. D78247

45. 388t875

46. A813672

47. Sr-01000872621

48. Q3981568

49. Sr-01000872621-2

50. W-107711

51. 4,4'-methylenebis(1,2,4-thiadiazinane) 1,1,1',1'-tetraoxide

52. 4,4'-methylene-bis(tetrahydro-1,2,4-thiadiazine-1,1-dioxide)

53. 4-[(1,1-dioxido-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide #

2.4 Create Date
2005-03-27
3 Chemical and Physical Properties
Molecular Weight 284.4 g/mol
Molecular Formula C7H16N4O4S2
XLogP3-1.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count8
Rotatable Bond Count2
Exact Mass284.06129735 g/mol
Monoisotopic Mass284.06129735 g/mol
Topological Polar Surface Area116 Ų
Heavy Atom Count17
Formal Charge0
Complexity419
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Anti-Infective Agents

Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)


Anti-Infective Agents, Local

Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. (See all compounds classified as Anti-Infective Agents, Local.)


4.2 ATC Code

B - Blood and blood forming organs

B05 - Blood substitutes and perfusion solutions

B05C - Irrigating solutions

B05CA - Antiinfectives

B05CA05 - Taurolidine


API SUPPLIERS

read-more
read-more

01

Biophore India Pharmaceuticals Pvt...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Biophore

02

Apothecon Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Apothecon Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

CorMedix

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

CorMedix

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Excella GmbH

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Excella GmbH

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

05

Sionc Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Sionc Pharmaceuticals

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

HSBio

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

HSBio

South Korea

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

07

Abhilasha Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Abhilasha Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WCInactive-api NDC KDMF arrow-down VMF Others AUDIT
blank

08

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

09

Abhilasha Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Abhilasha Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank

10

Yuil Pharm

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Organic Process R&D
Not Confirmed
arrow

Yuil Pharm

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Organic Process R&D
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

CorMedix intends to use the net proceeds for research and the development of product candidates, including Taurolidine for the treatment of neuroblastoma.


Lead Product(s): Taurolidine,Glecaprevir,Pibrentasvir,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Antibiotic

Sponsor: RBC Capital Markets

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 27, 2025

blank

01

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : CorMedix intends to use the net proceeds for research and the development of product candidates, including Taurolidine for the treatment of neuroblastoma.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Undisclosed

June 27, 2025

blank

Details:

CorMedix intends to use the net proceeds for research and the development of product candidates, including Taurolidine for the treatment of neuroblastoma.


Lead Product(s): Taurolidine,Inapplicable

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: PreclinicalProduct Type: Antibiotic

Sponsor: RBC Capital Markets

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 26, 2025

blank

02

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Lead Product(s) : Taurolidine,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : RBC Capital Markets

Deal Size : $85.0 million

Deal Type : Public Offering

Details : CorMedix intends to use the net proceeds for research and the development of product candidates, including Taurolidine for the treatment of neuroblastoma.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Undisclosed

June 26, 2025

blank

Details:

Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Catheter-Related Infections.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 12, 2025

blank

03

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Catheter-Related Infections.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

February 12, 2025

blank
  • Development Update

Details:

LDX-01 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Substance-Related Disorders.


Lead Product(s): LDX-01,Taurolidine

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Undisclosed

Sponsor: Ministere de la Sante et des Services Sociaux | Health Canada

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 23, 2025

blank

04

Centre Hospitalier de l'Universite de Montreal

Country
arrow
PackExpo
Not Confirmed

Centre Hospitalier de l'Universite de Montreal

Country
arrow
PackExpo
Not Confirmed

Lead Product(s) : LDX-01,Taurolidine

Therapeutic Area : Psychiatry/Psychology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Ministere de la Sante et des Services Sociaux | Health Canada

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : LDX-01 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Substance-Related Disorders.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

January 23, 2025

blank

Details:

Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Catheter-Related Infections.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 04, 2024

blank

05

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Catheter-Related Infections.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

December 04, 2024

blank

Details:

Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Catheter-Related Infections.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 27, 2024

blank

06

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : Taurolidine is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Catheter-Related Infections.

Product Name : Undisclosed

Product Type : Antibiotic

Upfront Cash : Inapplicable

November 27, 2024

blank

Details:

Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Immunology Brand Name: Defencath

Study Phase: Approved FDFProduct Type: Antibiotic

Sponsor: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 19, 2024

blank

07

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : Through the agreement, Cordemix will supply DefenCath (taurolidine and heparin) to dialysis clinics for CRBSI in adult patients with kidney failure receiving chronic hemodialysis.

Product Name : Defencath

Product Type : Antibiotic

Upfront Cash : Undisclosed

September 19, 2024

blank
  • Deals

Details:

The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Infections and Infectious Diseases Brand Name: DefenCath

Study Phase: Approved FDFProduct Type: Antibiotic

Sponsor: CorMedix

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 28, 2024

blank

08

Undisclosed

Country
arrow
PackExpo
Not Confirmed

Undisclosed

Country
arrow
PackExpo
Not Confirmed

Details : The agreement aims for the supply of DefenCath, a combination of taurolidine, a thiadiazinane antimicrobial and heparin, an anti-coagulant, indicated to reduce catheter-related bloodstream infections.

Product Name : DefenCath

Product Type : Antibiotic

Upfront Cash : Undisclosed

May 28, 2024

blank

Details:

Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Immunology Brand Name: Defencath

Study Phase: Approved FDFProduct Type: Antibiotic

Sponsor: ARC Dialysis, LLC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement April 08, 2024

blank

09

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : Through the agreement, the company will focus on the supply and commercialization of DefenCath (taurolidine and heparin) for the treatment of catheter-related bloodstream infections.

Product Name : Defencath

Product Type : Antibiotic

Upfront Cash : Undisclosed

April 08, 2024

blank

Details:

CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.


Lead Product(s): Taurolidine,Heparin Sodium

Therapeutic Area: Nephrology Brand Name: Defencath

Study Phase: Phase IVProduct Type: Antibiotic

Sponsor: RBC Capital Markets

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 28, 2023

blank

10

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

CorMedix

U.S.A
arrow
PackExpo
Not Confirmed

Details : CorMedix intends to use the net proceeds for the commercialization of Taurolock Hep500 (taurolidine), approved to be instilled into catheter-based devices for hemodialysis in order to maintain patency of the vascular access device.

Product Name : Defencath

Product Type : Antibiotic

Upfront Cash : Undisclosed

June 28, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Geistlich Pharma

Switzerland
PREP
Not Confirmed
arrow

Geistlich Pharma

Switzerland
arrow
PREP
Not Confirmed

Taurolidine

Brand Name : Taurolin

Dosage Form : Solution For Injection

Dosage Strength : 2g/100ml

Packaging :

Approval Date : 12/10/1981

Application Number : 43668

Regulatory Info : Allowed

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 19388-87-5 / Taurolidine API manufacturers, exporters & distributors?

Taurolidine manufacturers, exporters & distributors 1

16

PharmaCompass offers a list of Taurolidine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Taurolidine manufacturer or Taurolidine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Taurolidine manufacturer or Taurolidine supplier.

PharmaCompass also assists you with knowing the Taurolidine API Price utilized in the formulation of products. Taurolidine API Price is not always fixed or binding as the Taurolidine Price is obtained through a variety of data sources. The Taurolidine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Taurolidine

Synonyms

19388-87-5, Taurolidin, Taurolin, Cyclo-taurolidine, (cyclo)-taurolidine, 4-[(1,1-dioxo-1,2,4-thiadiazinan-4-yl)methyl]-1,2,4-thiadiazinane 1,1-dioxide

Cas Number

19388-87-5

Unique Ingredient Identifier (UNII)

8OBZ1M4V3V

About Taurolidine

Taurolidine is a synthetic broad-spectrum antibiotic with antibacterial, anticoagulant and potential antiangiogenic activities. Taurolidine, derived from the amino acid taurine, binds to and neutralizes bacterial exotoxins and endotoxins, or lipopolysaccharides (LPS). Taurolidine binding to LPS prevents bacterial adherence to host epithelial cells, thereby prevents bacterial invasion of uninfected host cells. Although the mechanism underlying its antineoplastic activity has not been fully elucidated, it may be related to this agent's anti-adherence property. In addition, taurolidine also promotes apoptosis by inducing various apoptotic factors and suppresses the production of vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis.

Taurolidine Manufacturers

A Taurolidine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Taurolidine, including repackagers and relabelers. The FDA regulates Taurolidine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Taurolidine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Taurolidine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Taurolidine Suppliers

A Taurolidine supplier is an individual or a company that provides Taurolidine active pharmaceutical ingredient (API) or Taurolidine finished formulations upon request. The Taurolidine suppliers may include Taurolidine API manufacturers, exporters, distributors and traders.

click here to find a list of Taurolidine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Taurolidine USDMF

A Taurolidine DMF (Drug Master File) is a document detailing the whole manufacturing process of Taurolidine active pharmaceutical ingredient (API) in detail. Different forms of Taurolidine DMFs exist exist since differing nations have different regulations, such as Taurolidine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Taurolidine DMF submitted to regulatory agencies in the US is known as a USDMF. Taurolidine USDMF includes data on Taurolidine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Taurolidine USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Taurolidine suppliers with USDMF on PharmaCompass.

Taurolidine KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Taurolidine Drug Master File in Korea (Taurolidine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Taurolidine. The MFDS reviews the Taurolidine KDMF as part of the drug registration process and uses the information provided in the Taurolidine KDMF to evaluate the safety and efficacy of the drug.

After submitting a Taurolidine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Taurolidine API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Taurolidine suppliers with KDMF on PharmaCompass.

Taurolidine WC

A Taurolidine written confirmation (Taurolidine WC) is an official document issued by a regulatory agency to a Taurolidine manufacturer, verifying that the manufacturing facility of a Taurolidine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Taurolidine APIs or Taurolidine finished pharmaceutical products to another nation, regulatory agencies frequently require a Taurolidine WC (written confirmation) as part of the regulatory process.

click here to find a list of Taurolidine suppliers with Written Confirmation (WC) on PharmaCompass.

Taurolidine NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Taurolidine as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Taurolidine API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Taurolidine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Taurolidine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Taurolidine NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Taurolidine suppliers with NDC on PharmaCompass.

Taurolidine GMP

Taurolidine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Taurolidine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Taurolidine GMP manufacturer or Taurolidine GMP API supplier for your needs.

Taurolidine CoA

A Taurolidine CoA (Certificate of Analysis) is a formal document that attests to Taurolidine's compliance with Taurolidine specifications and serves as a tool for batch-level quality control.

Taurolidine CoA mostly includes findings from lab analyses of a specific batch. For each Taurolidine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Taurolidine may be tested according to a variety of international standards, such as European Pharmacopoeia (Taurolidine EP), Taurolidine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Taurolidine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty